Literature DB >> 24715425

Effects of Liuwei Dihuang Granule ([symbols; see text]) on the outcomes of in vitro fertilization pre-embryo transfer in infertility women with Kidney-yin deficiency syndrome and the proteome expressions in the follicular fluid.

Fang Lian1, Hai-cui Wu, Zhen-gao Sun, Ying Guo, Lei Shi, Ming-yue Xue.   

Abstract

OBJECTIVE: To observe the effects of Liuwei Dihuang Granule ([symbols; see text], LDG) for tonifying Kidney (Shen) on the outcomes of in vitro fertilization pre-embryo transfer (IVF-ET) of infertility women with Kidney-yin deficiency syndrome and to explore its mechanism by detecting the proteome expression in the follicular fluid.
METHODS: Sixty-six infertility patients of Kidney-yin deficiency syndrome who would undergo IVF-ET, were randomly assigned to a treatment group and a control group according to a random number table, 33 cases in each group. Another 33 cases of non-Kidney-yin deficiency syndrome was taken as a syndrome-control group. Besides Western routine therapy, LDG was given 3 menstrual cycles before IVF to the treatment group, and a placebo granule to the control and syndrome-control groups. The scores of Kidney-yin deficiency symptoms (sore waist and knees, dry vagina, dysphoria with feverish sensation in the chest, palms and soles, etc.) were assessed, the number of retrieved oocytes, rates of high quality oocytes and embryos, fertility rate and clinical pregnancy rate were recorded, and the follicular fluid was collected on the day when the ovum was picked up, the differential protein expression was detected using two-dimensional gel electrophoresis, and then, matrix assisted laser desorption ionization time-of flight mass spectrometry (MALDI-TOF-MS) was applied to identify the proteins.
RESULTS: The syndrome score in the treatment group decreased significantly from 16.09±2.58 to 8.67±2.13, while it changed insignificantly in the control group, with a significant difference in the lowering score between the two groups (P<0.05); the high quality rates of oocytes and embryos and clinical pregnancy rate were all superior in the treatment group to the control group (82.29% vs 78.08%, 76.76% vs 68.79%, 63.64% vs 36.36%, all P<0.05). The protein expression map from the follicular fluid showed that compared with the control group, 33 differential protein expressions were found in the syndrome-control group, among which 18 were down-regulated, and 15 up-regulated; in the treatment group 28 differential protein expressions were found, among which 15 were down-regulated, and 13 up-regulated. Through MALDI-TOF-MS, 14 proteins were identified (P<0.05).
CONCLUSIONS: For the infertility patients undergoing IVF, LDG could alleviate clinical symptoms, improve rates of high quality oocytes and embryos, so as to raise clinical pregnancy rate. The mechanism may be through regulating proteome expression in the follicular fluid to improve the developmental microenvironment for oocytes which would lead to a successful embryo implantation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24715425     DOI: 10.1007/s11655-014-1712-y

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  17 in total

Review 1.  [Participation of the follicular fluid in follicular development, oocyte maturation and spermatic function].

Authors:  G Durán Reyes; A M Rosales; J J Hicks Gómez
Journal:  Ginecol Obstet Mex       Date:  1997-08

2.  Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass.

Authors:  Nora Klöting; Timothy E Graham; Janin Berndt; Susan Kralisch; Peter Kovacs; Christopher J Wason; Mathias Fasshauer; Michael R Schön; Michael Stumvoll; Matthias Blüher; Barbara B Kahn
Journal:  Cell Metab       Date:  2007-07       Impact factor: 27.287

3.  Embryo scoring as a prognostic tool in IVF treatment.

Authors:  F Puissant; M Van Rysselberge; P Barlow; J Deweze; F Leroy
Journal:  Hum Reprod       Date:  1987-11       Impact factor: 6.918

4.  Apolipoprotein AI efficiently binds to and mediates cholesterol and phospholipid efflux from human but not rat aortic smooth muscle cells.

Authors:  G A Francis; M Tsujita; T L Terry
Journal:  Biochemistry       Date:  1999-12-07       Impact factor: 3.162

5.  Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans.

Authors:  M Eriksson; L A Carlson; T A Miettinen; B Angelin
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

6.  Apolipoprotein E is a putative autocrine regulator of the rat ovarian theca cell compartment.

Authors:  C V Zerbinatti; L P Mayer; R G Audet; C A Dyer
Journal:  Biol Reprod       Date:  2001-04       Impact factor: 4.285

7.  Efficacy of fusion peptide homologs in blocking cell lysis and HIV-induced fusion.

Authors:  K A Silburn; D A McPhee; A L Maerz; P Poumbourios; R G Whittaker; A Kirkpatrick; W G Reilly; M K Manthey; C C Curtain
Journal:  AIDS Res Hum Retroviruses       Date:  1998-03-20       Impact factor: 2.205

8.  Apolipoproteins A-I and A-II downregulate neutrophil functions.

Authors:  Cristiane Jaciara Furlaneto; Fernanda Pereira Ribeiro; Elaine Hatanaka; Glaucia Mendes Souza; Marco A Cassatella; Ana Campa
Journal:  Lipids       Date:  2002-09       Impact factor: 1.880

9.  Role of VLDL/chylomicron in amyloid formation in familial amyloidotic polyneuropathy.

Authors:  Xuguo Sun; Yukio Ando; Katsuki Haraoka; Shoichi Katsuragi; Taro Yamashita; Sonoka Yamashita; Miyo Okajima; Hisayasu Terazaki; Hiroaki Okabe
Journal:  Biochem Biophys Res Commun       Date:  2003-11-14       Impact factor: 3.575

10.  Moderate exercise may attenuate some aspects of immunosenescence.

Authors:  Nadzieja Drela; Ewa Kozdron; Piotr Szczypiorski
Journal:  BMC Geriatr       Date:  2004-09-29       Impact factor: 3.921

View more
  8 in total

1.  Incorporating pattern identification of Chinese medicine into precision medicine: An integrative model for individualized medicine.

Authors:  Jin-gen Li; Hao Xu
Journal:  Chin J Integr Med       Date:  2015-10-31       Impact factor: 1.978

2.  Erzhi Tiangui Granules Improve In Vitro Fertilization Outcomes in Infertile Women with Advanced Age.

Authors:  Jinlong Sun; Jing-Yan Song; Yao Dong; Shan Xiang; Qiong Guo
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-12       Impact factor: 2.629

3.  Zisheng Shenqi decoction ameliorates monosodium urate crystal-induced gouty arthritis in rats through anti-inflammatory and anti-oxidative effects.

Authors:  Jieru Han; Ying Xie; Fangyu Sui; Chunhong Liu; Xiaowei Du; Chenggang Liu; Xiaoling Feng; Deyou Jiang
Journal:  Mol Med Rep       Date:  2016-07-18       Impact factor: 2.952

Review 4.  Meta-Analysis of Chinese Traditional Medicine Bushen Huoxue Prescription for Endometriosis Treatment.

Authors:  Jing Shan; Wen Cheng; Dong-Xia Zhai; Dan-Ying Zhang; Rui-Pin Yao; Ling-Ling Bai; Zai-Long Cai; Yu-Huan Liu; Chao-Qin Yu
Journal:  Evid Based Complement Alternat Med       Date:  2017-11-23       Impact factor: 2.629

Review 5.  Acupuncture for in vitro fertilization in women with poor ovarian response: a systematic review.

Authors:  Soobin Jang; Kyeong Han Kim; Ji Hee Jun; Sooseong You
Journal:  Integr Med Res       Date:  2020-02-27

Review 6.  Recent Advance in Applications of Proteomics Technologies on Traditional Chinese Medicine Research.

Authors:  Qing Ji; Fangshi Zhu; Xuan Liu; Qi Li; Shi-Bing Su
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-19       Impact factor: 2.629

7.  Integrated targeted serum metabolomic profile and its association with gender, age, disease severity, and pattern identification in acne.

Authors:  Min Hee Kim; In Jin Ha; Eunok Kim; Kyuseok Kim
Journal:  PLoS One       Date:  2020-01-17       Impact factor: 3.240

Review 8.  Autophagy as a Therapeutic Target of Natural Products Enhancing Embryo Implantation.

Authors:  Hyerin Park; Minkyoung Cho; Yoonju Do; Jang-Kyung Park; Sung-Jin Bae; Jongkil Joo; Ki-Tae Ha
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.